Search results

A new nasal pertussis vaccine against whooping cough has shown promising results. The vaccine was shown to be safe and to work against whooping cough in a study conducted in healthy adults. Professor Qiushui He and Project Researcher Alex-Mikael Barkoff from the InFLAMES research flagship of the University of Turku participated in the study. The research article was published in the esteemed medical journal Lancet.

Although vaccination programmes against pertussis are very effective in Europe, new Finnish study shows that the disease is still very common among middle-aged adults in various European countries. At the same time, the results show that the disease is underdiagnosed as the annually reported figures are considerably lower than those discovered in the study.

A research team of 22 researchers from 11 countries investigating means to defeat pertussis, or whooping cough, has received €28 million funding for creating a novel vaccine. Participants from Finland include a team of researchers from the University of Turku, who explore the resistance created by the vaccine and the immunity caused by pertussis.

​Children cannot be given the vaccine until the age of 2–3 months. For people without vaccination, pertussis can be lethal.